Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-20T02:26:19.905Z Has data issue: false hasContentIssue false
  • English
  • Français

Lipid-lowering drug therapies: the evidence

Published online by Cambridge University Press:  28 February 2007

Chris Packard
Chris Packard
Affiliation:
Department of Pathological Biochemistry, Glasgow Royal Infirmary UniversityNHS Trust, Queen Elizabeth Building, Glasgow G31 2ER, UK
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

Lipid-lowering drug therapiesStatinsMyocardial infarction risk
Type
Meeting Report
Information
Proceedings of the Nutrition Society , Volume 59 , Issue 3 , August 2000 , pp. 423 - 424
Copyright
Copyright © The Nutrition Society 2000

References

Downs, JR, Clearfield, M, Weis, S, Whitney, E, Shapiro, Dr, Beere, PA, Langendorfer, A, Stein, EA, Kruyer, W & Gotto, AM (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 279, 1615–1622.CrossRefGoogle ScholarPubMed
Sacks, FM, Pfeffer, MA, Moye, LA, Rouleau, JL, Rutherford, JD, Cole, TG, Brown, L, Warnica, JW, Arnold, JMO, Wun, C-C, Davis, BR & Braunwald, E (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 335, 1001–1009.CrossRefGoogle ScholarPubMed
Scandinavian Simvastatin Survival Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian Survival Study. Lancet 344, 1383–1389.Google Scholar
Shepherd, J, Cobbe, SM, Ford, I, Isles, CG, Lorimer, AR, Macfarlane, PW, McKillop, JH & Packard, C (1995) For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. New England Journal of Medicine 333, 1301–1307.CrossRefGoogle Scholar
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 339, 1349–1357.CrossRefGoogle Scholar